{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:17:52Z","timestamp":1707524272899},"reference-count":40,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,6,30]]},"DOI":"10.7759\/cureus.16048","type":"journal-article","created":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T07:20:19Z","timestamp":1625037619000},"source":"Crossref","is-referenced-by-count":0,"title":["Correlation of the Expression of BRAF V600E Mutation With Various Phenotypic Expressions of Thyroid Neoplasms"],"prefix":"10.7759","author":[{"given":"Volga","family":"Harikrishnan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shantha","family":"Kumari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Subramaniam","family":"Ramkumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramalingam","family":"Sankaran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sudha","family":"Ramalingam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thiagarajan","family":"Sairam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Thyroid gland","author":"Carcangiu ML","year":"2006","unstructured":"Carcangiu ML. Thyroid gland. Histology for Pathologists, Third Edition. Mills SE (ed): Lippincott Williams & Wilkins, Philadelphia; 2006."},{"key":"ref2","article-title":"World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Endocrine Organs","author":"DeLellis R","year":"2004","unstructured":"DeLellis R, Lloyd RV, Heitz PU, Eng C. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Endocrine Organs. IARC Press, Lyon; 2004."},{"key":"ref3","article-title":"The endocrine system","author":"Abul K","year":"2004","unstructured":"Abul K, Abbas AM. The endocrine system. Robbins and Cotran Pathological Basis of Disease. Kumar V, Fausto N, Abbas A (ed): Saunders, New York; 2004. 1155-83."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.3880312","article-title":"Immunohistochemical diagnosis of papillary thyroid carcinoma","volume":"14","author":"Cheung CC","year":"2001","unstructured":"Cheung CC, Ezzat S, Freeman JL, Rosen IB, Asa SL. Immunohistochemical diagnosis of papillary thyroid carcinoma. Mod Pathol. 2001, 14:338-42. 10.1038\/modpathol.3880312","journal-title":"Mod Pathol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.5114\/pjp.2019.93131","article-title":"CD56, CD57, HBME1, CK19, Galectin-3 and p63 immunohistochemical stains in differentiating diagnosis of thyroid benign\/malign lesions and NIFTP","volume":"70","author":"Tastekin E","year":"2019","unstructured":"Tastekin E, Keskin E, Can N, et al.. CD56, CD57, HBME1, CK19, Galectin-3 and p63 immunohistochemical stains in differentiating diagnosis of thyroid benign\/malign lesions and NIFTP. Pol J Pathol. 2019, 70:286-94. 10.5114\/pjp.2019.93131","journal-title":"Pol J Pathol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-0607","article-title":"BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study","volume":"93","author":"Elisei R","year":"2008","unstructured":"Elisei R, Ugolini C, Viola D, et al.. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. J Clin Endocrinol Metab. 2008, 93:3943-9. 10.1210\/jc.2008-0607","journal-title":"J Clin Endocrinol Metab"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0231341","article-title":"BRAF and KRAS mutations in papillary thyroid carcinoma in the United Arab Emirates","volume":"15","author":"Al-Salam S","year":"2020","unstructured":"Al-Salam S, Sharma C, Afandi B, Al Dahmani K, Al-Zahrani AS, Al Shamsi A, Al Kaabi J. BRAF and KRAS mutations in papillary thyroid carcinoma in the United Arab Emirates. PLoS One. 2020, 15:e0231341. 10.1371\/journal.pone.0231341","journal-title":"PLoS One"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.5858\/2006-130-1057-PTCAO","article-title":"Papillary thyroid carcinoma: an overview","volume":"130","author":"Al-Brahim N","year":"2006","unstructured":"Al-Brahim N, Asa SL. Papillary thyroid carcinoma: an overview. Arch Pathol Lab Med. 2006, 130:1057-62. 10.5858\/2006-130-1057-PTCAO","journal-title":"Arch Pathol Lab Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1210\/er.2007-0007","article-title":"BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications","volume":"28","author":"Xing M","year":"2007","unstructured":"Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev. 2007, 28:742-62. 10.1210\/er.2007-0007","journal-title":"Endocr Rev"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3390\/cells10051082","article-title":"The genomic landscape of thyroid cancer tumourigenesis and implications for immunotherapy","volume":"10","author":"Singh A","year":"2021","unstructured":"Singh A, Ham J, Po JW, Niles N, Roberts T, Lee CS. The genomic landscape of thyroid cancer tumourigenesis and implications for immunotherapy. Cells. 2021, 10:1082. 10.3390\/cells10051082","journal-title":"Cells"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.5858\/2010-0664-RAIR.1","article-title":"Molecular diagnostics of thyroid tumors","volume":"135","author":"Nikiforov YE","year":"2011","unstructured":"Nikiforov YE. Molecular diagnostics of thyroid tumors. Arch Pathol Lab Med. 2011, 135:569-77. 10.5858\/2010-0664-RAIR.1","journal-title":"Arch Pathol Lab Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2020.153037","article-title":"Effect of BRAF V600E mutation detection of fine-needle aspiration biopsy on diagnosis and treatment guidance of papillary thyroid carcinoma","volume":"216","author":"Qi W","year":"2020","unstructured":"Qi W, Shi C, Zhang P, Feng L, Wang J, Chen D. Effect of BRAF V600E mutation detection of fine-needle aspiration biopsy on diagnosis and treatment guidance of papillary thyroid carcinoma. Pathol Res Pract. 2020, 216:153037. 10.1016\/j.prp.2020.153037","journal-title":"Pathol Res Pract"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.suc.2009.06.012","article-title":"Molecular markers in thyroid cancer diagnostics","volume":"89","author":"Kato MA","year":"2009","unstructured":"Kato MA, Fahey TJ 3rd. Molecular markers in thyroid cancer diagnostics. Surg Clin North Am. 2009, 89:1139-55. 10.1016\/j.suc.2009.06.012","journal-title":"Surg Clin North Am"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.21037\/gs.2017.11.07","article-title":"Molecular testing in the diagnosis of differentiated thyroid carcinomas","volume":"7","author":"Ferrari SM","year":"2018","unstructured":"Ferrari SM, Fallahi P, Ruffilli I, et al.. Molecular testing in the diagnosis of differentiated thyroid carcinomas. Gland Surg. 2018, 7:S19-29. 10.21037\/gs.2017.11.07","journal-title":"Gland Surg"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1177\/107327480601300205","article-title":"Genetic considerations in thyroid cancer","volume":"13","author":"Patel KN","year":"2006","unstructured":"Patel KN, Singh B. Genetic considerations in thyroid cancer. Cancer Control. 2006, 13:111-8. 10.1177\/107327480601300205","journal-title":"Cancer Control"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathol-121808-102139","article-title":"Genomic hallmarks of thyroid neoplasia","volume":"13","author":"Giordano TJ","year":"2018","unstructured":"Giordano TJ. Genomic hallmarks of thyroid neoplasia. Annu Rev Pathol. 2018, 13:141-62. 10.1146\/annurev-pathol-121808-102139","journal-title":"Annu Rev Pathol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/path.2796","article-title":"KRAS and BRAF: drug targets and predictive biomarkers","volume":"223","author":"Vakiani E","year":"2011","unstructured":"Vakiani E, Solit DB. KRAS and BRAF: drug targets and predictive biomarkers. J Pathol. 2011, 223:219-29. 10.1002\/path.2796","journal-title":"J Pathol"},{"key":"ref18","article-title":"Genetic basis and gene therapy trials for thyroid cancer","volume":"7","author":"Al-Humadi H","year":"2010","unstructured":"Al-Humadi H, Zarros A, Al-Saigh R, Liapi C. Genetic basis and gene therapy trials for thyroid cancer. Cancer Genomics Proteomics. 2010, 7:31-49.","journal-title":"Cancer Genomics Proteomics"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3390\/cells9040830","article-title":"Combinatorial therapies in thyroid cancer: an overview of preclinical and clinical progresses","volume":"9","author":"Laetitia G","year":"2020","unstructured":"Laetitia G, Sven S, Fabrice J. Combinatorial therapies in thyroid cancer: an overview of preclinical and clinical progresses. Cells. 2020, 9:830. 10.3390\/cells9040830","journal-title":"Cells"},{"key":"ref20","article-title":"Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF","volume":"116","author":"Wan PTC","year":"2004","unstructured":"Wan PTC, Garnett MJ, Roe SM, et al.. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell. 2004, 116:855-67.","journal-title":"Cell"},{"key":"ref21","article-title":"The BRAFV600E mutation analysis and risk stratification in papillary thyroid carcinoma","volume":"64","author":"Scheffel RS","year":"2021","unstructured":"Scheffel RS, de Cristo AP, Romitti M, et al.. The BRAFV600E mutation analysis and risk stratification in papillary thyroid carcinoma. Arch Endocrinol Metab. 2021, 64:751-7.","journal-title":"Arch Endocrinol Metab"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0b013e318148563d","article-title":"The prevalence and prognostic value of BRAF mutation in thyroid cancer","volume":"246","author":"Kebebew E","year":"2007","unstructured":"Kebebew E, Weng J, Bauer J, et al.. The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg. 2007, 246:466-70; discussion 470-1. 10.1097\/SLA.0b013e318148563d","journal-title":"Ann Surg"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1836","article-title":"Pathogenetic mechanisms in thyroid follicular-cell neoplasia","volume":"6","author":"Kondo T","year":"2006","unstructured":"Kondo T, Ezzat S, Asa SL. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer. 2006, 6:292-306. 10.1038\/nrc1836","journal-title":"Nat Rev Cancer"},{"key":"ref24","article-title":"Clinical significance of BRAF (V600E) mutation and Ki-67 labeling index in papillary thyroid carcinomas","volume":"27","author":"Nakayama H","year":"2007","unstructured":"Nakayama H, Yoshida A, Nakamura Y, et al.. Clinical significance of BRAF (V600E) mutation and Ki-67 labeling index in papillary thyroid carcinomas. Anticancer Res. 2007, 27:3645-9.","journal-title":"Anticancer Res"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1530\/EC-20-0420","article-title":"BRAF V600E and lymph node metastases in papillary thyroid cancer","volume":"9","author":"Chen P","year":"2020","unstructured":"Chen P, Pan L, Huang W, et al.. BRAF V600E and lymph node metastases in papillary thyroid cancer. Endocr Connect. 2020, 9:999-1008. 10.1530\/EC-20-0420","journal-title":"Endocr Connect"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1007\/s00411-021-00904-y","article-title":"Analysis of the association of BRAFV600E mutation and Ki-67 overexpression with clinical and pathological characteristics in papillary thyroid cancer","volume":"60","author":"Espenbetova M","year":"2021","unstructured":"Espenbetova M, Krykpayeva A, Zamanbekova Z, Zhumanbaeva Z, Azizov B, Mukanova A, Glushkova N. Analysis of the association of BRAFV600E mutation and Ki-67 overexpression with clinical and pathological characteristics in papillary thyroid cancer. Radiat Environ Biophys. 2021, 60:233-41. 10.1007\/s00411-021-00904-y","journal-title":"Radiat Environ Biophys"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1677\/ERC-07-0212","article-title":"BRAF(V600E) mutation and the biology of papillary thyroid cancer","volume":"15","author":"Frasca F","year":"2008","unstructured":"Frasca F, Nucera C, Pellegriti G, et al.. BRAF(V600E) mutation and the biology of papillary thyroid cancer. Endocr Relat Cancer. 2008, 15:191-205. 10.1677\/ERC-07-0212","journal-title":"Endocr Relat Cancer"},{"key":"ref28","article-title":"Utility of BRAF V600E mutation detection in cytologically indeterminate thyroid nodules","volume":"3","author":"Rowe LR","year":"2006","unstructured":"Rowe LR, Bentz BG, Bentz JS. Utility of BRAF V600E mutation detection in cytologically indeterminate thyroid nodules. Cytojournal. 2006, 3:10.","journal-title":"Cytojournal"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2478","article-title":"BRAFV600E mutation analysis in fine-needle aspiration cytology specimens for diagnosis of thyroid nodules: the influence of false-positive and false-negative results","volume":"8","author":"Zhao CK","year":"2019","unstructured":"Zhao CK, Zheng JY, Sun LP, Xu RY, Wei Q, Xu HX. BRAFV600E mutation analysis in fine-needle aspiration cytology specimens for diagnosis of thyroid nodules: the influence of false-positive and false-negative results. Cancer Med. 2019, 8:5577-89. 10.1002\/cam4.2478","journal-title":"Cancer Med"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1186\/s12957-017-1266-5","article-title":"False-negative BRAF V600E mutation results on fine-needle aspiration cytology of papillary thyroid carcinoma","volume":"15","author":"Paek SH","year":"2017","unstructured":"Paek SH, Kim BS, Kang KH, Kim HS. False-negative BRAF V600E mutation results on fine-needle aspiration cytology of papillary thyroid carcinoma. World J Surg Oncol. 2017, 15:202. 10.1186\/s12957-017-1266-5","journal-title":"World J Surg Oncol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1530\/eje.1.02072","article-title":"Detection of BRAF mutation in thyroid papillary carcinomas by mutant allele-specific PCR amplification (MASA)","volume":"154","author":"Sapio MR","year":"2006","unstructured":"Sapio MR, Posca D, Troncone G, et al.. Detection of BRAF mutation in thyroid papillary carcinomas by mutant allele-specific PCR amplification (MASA). Eur J Endocrinol. 2006, 154:341-8. 10.1530\/eje.1.02072","journal-title":"Eur J Endocrinol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2007.03077.x","article-title":"BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma","volume":"68","author":"Costa AM","year":"2008","unstructured":"Costa AM, Herrero A, Fresno MF, Heymann J, Alvarez JA, Cameselle-Teijeiro J, Garc\u00eda-Rost\u00e1n G. BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma. Clin Endocrinol (Oxf). 2008, 68:618-34. 10.1111\/j.1365-2265.2007.03077.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1002\/jso.20700","article-title":"Pathology and genetics of thyroid carcinoma","volume":"94","author":"DeLellis RA","year":"2006","unstructured":"DeLellis RA. Pathology and genetics of thyroid carcinoma. J Surg Oncol. 2006, 94:662-9. 10.1002\/jso.20700","journal-title":"J Surg Oncol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1007\/s12022-021-09665-2","article-title":"Molecular pathology of poorly differentiated and anaplastic thyroid cancer: what do pathologists need to know?","volume":"32","author":"Volante M","year":"2021","unstructured":"Volante M, Lam AK, Papotti M, Tallini G. Molecular pathology of poorly differentiated and anaplastic thyroid cancer: what do pathologists need to know?. Endocr Pathol. 2021, 32:63-76. 10.1007\/s12022-021-09665-2","journal-title":"Endocr Pathol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1007\/s12022-021-09674-1","article-title":"Progression of papillary thyroid carcinoma to anaplastic carcinoma in metastatic lymph nodes: solid\/insular growth and hobnail cell change in lymph nodes are predictors of subsequent anaplastic transformation","author":"Odate T","year":"2021","unstructured":"Odate T, Oishi N, Kawai M, et al.. Progression of papillary thyroid carcinoma to anaplastic carcinoma in metastatic lymph nodes: solid\/insular growth and hobnail cell change in lymph nodes are predictors of subsequent anaplastic transformation. Endocr Pathol. 2021, 10.1007\/s12022-021-09674-1","journal-title":"Endocr Pathol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21073","article-title":"Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations","volume":"103","author":"Quiros RM","year":"2005","unstructured":"Quiros RM, Ding HG, Gattuso P, Prinz RA, Xu X. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations. Cancer. 2005, 103:2261-8. 10.1002\/cncr.21073","journal-title":"Cancer"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1206706","article-title":"BRAF mutations and RET\/PTC rearrangements are alternative events in the etiopathogenesis of PTC","volume":"22","author":"Soares P","year":"2003","unstructured":"Soares P, Trovisco V, Rocha AS, et al.. BRAF mutations and RET\/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene. 2003, 22:4578-80. 10.1038\/sj.onc.1206706","journal-title":"Oncogene"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1385\/ep:13:3:175","article-title":"Thyroid cancer and thyroiditis in Salta, Argentina: a 40-yr study in relation to iodine prophylaxis","volume":"13","author":"Harach HR","year":"2002","unstructured":"Harach HR, Escalante DA, Day ES. Thyroid cancer and thyroiditis in Salta, Argentina: a 40-yr study in relation to iodine prophylaxis. Endocr Pathol. 2002, 13:175-81. 10.1385\/ep:13:3:175","journal-title":"Endocr Pathol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1007\/s12022-008-9038-y","article-title":"Thyroid cancer, thyroiditis and dietary iodine: a review based on the Salta, Argentina model","volume":"19","author":"Harach HR","year":"2008","unstructured":"Harach HR, Ceballos GA. Thyroid cancer, thyroiditis and dietary iodine: a review based on the Salta, Argentina model. Endocr Pathol. 2008, 19:209-20. 10.1007\/s12022-008-9038-y","journal-title":"Endocr Pathol"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.18231\/2456-9267.2018.0024","article-title":"Papillary carcinoma thyroid presented with extensive local lymph nodal metastasis","volume":"3","author":"Jagtap SV","year":"2018","unstructured":"Jagtap SV, Patil D, Chetan, Gupta SO. Papillary carcinoma thyroid presented with extensive local lymph nodal metastasis. P Arch Cytol Histopathol Res. 2018, 3:113-5. 10.18231\/2456-9267.2018.0024","journal-title":"P Arch Cytol Histopathol Res"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/53487-correlation-of-the-expression-of-braf-v600e-mutation-with-various-phenotypic-expressions-of-thyroid-neoplasms","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:31:20Z","timestamp":1707507080000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/53487-correlation-of-the-expression-of-braf-v600e-mutation-with-various-phenotypic-expressions-of-thyroid-neoplasms"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,30]]},"references-count":40,"URL":"https:\/\/doi.org\/10.7759\/cureus.16048","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6,30]]}}}